Licensing status

Publication and contact information



Checkpoint kinase 1 (CHK1); protein CIP2A (KIAA1524; CIP2A)

Studies in human tumor samples and cell lines suggest CIP2A levels could help predict the efficacy of CHK1 inhibitors in cancer. In human tumor samples, elevated expression of CIP2A and the DNA damage response protein CHK1 was associated with decreased patient survival. In two human cancer cell lines, a CHK1 inhibitor decreased CIP2A expression and viability in the sensitive cell line but not in the resistant cell line. Next steps include evaluating CIP2A and CIP2A-regulated targets as predictors of response to CHK1 inhibitors in clinical trials.

SciBX 6(43); doi:10.1038/scibx.2013.1217
Published online Nov. 7, 2013

Patent applications filed covering inhibition of CIP2A; available for licensing

Khanna, A. et al. Cancer Res.; published Sept. 26, 2013;
Contact: Jukka Westermarck, University of Turku, Turku, Finland